All patients
corticosteroids: no corticosteroids: yes critical disease severe disease
Immunosuppressants drugs in COVID 19 all comers - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias death D28detailed results RECOVERY, 2022 0.87 [0.77; 0.98]
TOCOVID, 0 0.99 [0.02; 50.02]
0.87 [0.77 ; 0.98 ] RECOVERY, 2022, TOCOVID, 0 2 0% 8,426 moderate not evaluable death or transfer to ICUdetailed results BACC Bay Tocilizumab Trial, 2020 0.97 [0.50; 1.88]
0.97 [0.50 ; 1.88 ] BACC Bay Tocilizumab Trial, 2020 1 0% 242 NA not evaluable deathsdetailed results BACC Bay Tocilizumab Trial, 2020 1.52 [0.41; 5.62]
RECOVERY, 2022 0.87 [0.77; 0.98]
TOCOVID, 0 0.99 [0.02; 50.02]
0.87 [0.78 ; 0.99 ] BACC Bay Tocilizumab Trial, 2020, RECOVERY, 2022, TOCOVID, 0 3 0% 8,668 moderate not evaluable clinical deteriorationdetailed results BACC Bay Tocilizumab Trial, 2020 1.11 [0.59; 2.09]
1.11 [0.59 ; 2.09 ] BACC Bay Tocilizumab Trial, 2020 1 0% 242 NA not evaluable clinical improvementdetailed results BACC Bay Tocilizumab Trial, 2020 1.06 [0.80; 1.41]
1.06 [0.80 ; 1.41 ] BACC Bay Tocilizumab Trial, 2020 1 0% 242 NA not evaluable clinical improvement (time to event analysis only)detailed results sarimulab phase 2 low dose, 0 0.96 [0.53; 1.73]
0.96 [0.53 ; 1.73 ] sarimulab phase 2 low dose, 0 1 0% 247 NA not evaluable death or ventilationdetailed results BACC Bay Tocilizumab Trial, 2020 0.83 [0.38; 1.81]
NCT04310228-FAVI (Zhao), 2020 3.60 [0.13; 102.66]
RECOVERY, 2022 0.90 [0.81; 0.99]
0.90 [0.81 ; 0.99 ] BACC Bay Tocilizumab Trial, 2020, NCT04310228-FAVI (Zhao), 2020, RECOVERY, 2022 3 0% 8,159 moderate not evaluable mechanical ventilationdetailed results RECOVERY, 2022 0.87 [0.74; 1.02]
0.87 [0.74 ; 1.02 ] RECOVERY, 2022 1 0% 7,905 NA not evaluable radiologic improvement (14-day)detailed results NCT04310228-FAVI (Zhao), 2020 0.32 [0.06; 1.63]
0.32 [0.06 ; 1.63 ] NCT04310228-FAVI (Zhao), 2020 1 0% NA not evaluable serious adverse eventsdetailed results BACC Bay Tocilizumab Trial, 2020 1.21 [0.58; 2.53]
1.21 [0.58 ; 2.53 ] BACC Bay Tocilizumab Trial, 2020 1 0% 242 NA not evaluable adverse eventsdetailed results NCT04310228-FAVI (Zhao), 2020 0.60 [0.05; 6.80]
0.60 [0.05 ; 6.80 ] NCT04310228-FAVI (Zhao), 2020 1 0% 12 NA not evaluable 0.2 2.0 1.0 relative treatment effect www.metaEvidence.org 2024-05-01 17:30 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 94
- treatments: 596,1437,600,652,557,635,1236,553,628,646,645,607,395,920,1438,927,932,931,1263,599,614,942,1436,928,923,535,1046,727,818,606,954,964,962,963,1045,638,677,627,533,526
- roots T: 290
